LEUCODININE B 10%  
Mequinol ointment

Local treatment of acquired melanin hyperpigmentations, in particular: melasma, post-inflammatory or chemical (parfume) melanosis

**FORMS and PRESENTATIONS**
Ointment: Tube of 30 g.

**COMPOSITION**
Per tube:
Mequinol (INN) 3 g
Excipients: macrogol 300, macrogol 1 500.

**INDICATIONS**
Local treatment of acquired melanin hyperpigmentations, in particular: melasma, post-inflammatory or chemical (perfume) melanosis.

**DOSAGE AND ADMINISTRATION**
2 applications per day.
The frequency of application can be reduced as improvement is seen. When depigmentation is obtained, it is preferable to continue using the treatment at least once a week. Local photoprotection is necessary.

**CONTRAINDICATIONS**
Hypersensitivity to mequinol.
Children under 12 years.

**WARNINGS and PRECAUTIONS FOR USE**
Avoid sun exposure of hyperpigmented areas or ensure local photoprotection by using a total sunscreen cream both during and after treatment.
Avoid contact with eyes and mucous membranes.

**PREGNANCY and LACTATION**
Pregnancy:
In exposed pregnancies, no fetal malformation or toxicity has been reported to date. However, the follow-up of pregnancies exposed to mequinol is insufficient to rule out a risk. Therefore, as a precaution, this medicinal product should preferably not be used during pregnancy.

Lactation:
In the absence of data, the use of this medicinal product should be avoided during lactation.

**UNDESIRABLE EFFECTS**
Irritation or sensitization reactions to mequinol (rare).
Risk of post-inflammatory hypermelanosis.
Cases of nonhomogeneous leukomelanoderma en confetti at the application site, and hypomelanosis occurring far from the treated areas, have been reported.

**PHARMACODYNAMICS**
Translator: there seems to be a mistake here Réactions à type d'irritation ou de sensibilisation au méquinol (rare).
Risque d'hypermélanose post-inflammatoire.
Des cas de leucomélanodermie inhomogène avec dépigmentation en confettis au site d'application et quelques cas d'hypomélanose survenant à distance des zones traitées ont été rapportés.

**INCOMPATIBILITIES**
Do not mix with other creams or ointments (risk of incompatibility, in particular with oxidants or metallic compounds).

**PRESCRIPTION/SUPPLY/REIMBURSEMENT**
Not reimbursed by national health insurance.
Marketing Authorization Holder: CLS Pharma. contact@clspharma.fr